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Synopsis
Mutations in MECP2 (methyl-CpG-binding protein 2) are linked to the severe postnatal neurodevelopmental disorder
RTT (Rett syndrome). MeCP2 was originally characterized as a transcriptional repressor that preferentially bound
methylated DNA; however, recent results indicate MeCP2 is a multifunctional protein. MeCP2 binding is now associated
with certain expressed genes and involved in nuclear organization as well, indicating that its gene regulatory function
is context-dependent. In addition, MeCP2 is proposed to regulate mRNA splicing and a mouse model for RTT shows
aberrant mRNA splicing. To further understand MeCP2 and potential roles in RTT pathogenesis, we have employed
a biochemical approach to identify the MeCP2 protein complexes present in the mammalian brain. We show that
MeCP2 exists in at least four biochemically distinct pools in the brain and characterize one novel brain-derived MeCP2
complex that contains the splicing factor Prpf3 (pre-mRNA processing factor 3). MeCP2 directly interacts with Prpf3
in vitro and in vivo and many MECP2 RTT truncations disrupt the MeCP2–Prpf3 complex. In addition, MeCP2 and
Prpf3 associate in vivo with mRNAs from genes known to be expressed when their promoters are associated with
MeCP2. These results support a role for MeCP2 in mRNA biogenesis and suggest an additional mechanism for RTT
pathophysiology.
Key words: methyl CpG-binding domain (MBD), methyl-CpG-binding protein 2 (MeCP2), pre-mRNA processing factor
3 (Prpf3), Rett syndrome, RNA
INTRODUCTION
MeCP2 (methyl-CpG-binding protein 2) was originally identi-
fied by its ability to preferentially bind double-stranded DNA
containing symmetrically methylated CpG dinucleotides and is
the founding member of the MBD (methyl-CpG-binding domain)
family of proteins [1,2]. The first biological role for MeCP2 was
illustrated by showing that the protein interacts with methyl-
ated DNA in vivo and could repress transcription by association
with a transcriptional co-repressor complex containing Sin3A
and HDAC (histone deacetylase) [3–5]. In 1999, a genetic ana-
lysis identified mutations in MECP2 as causal for RTT (Rett
syndrome), providing the first direct link between an epigen-
etic regulator and a human disease [6]. RTT is a severe postnatal
neurodevelopmental disorder and one of the most common causes
of mental retardation in females [7]. First described in 1966 by
Andreas Rett [8], RTT is characterized by a period of apparently
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Abbreviations used: Cdk10, cyclin-dependent kinase 10; ChIP, chromatin immunoprecipitation; co-IP, co-immunoprecipitation; CV, column volume; DTT, dithiothreitol; GST, glutathione
transferase; HA, haemagglutinin; IP, immunoprecipitation; MeCP2, methyl-CpG-binding protein 2; MBD, methyl-CpG-binding domain; MS/MS, tandem MS; Prpf3, pre-mRNA processing
factor 3; RIP, RNA IP; RT–PCR, reverse transcription–PCR; RTT, Rett syndrome; Sdccag1, serologically defined colon cancer antigen 1; TRD, transcription repression domain.
1 To whom correspondence should be addressed (email pjones@bbri.org).
normal development from birth to 6–18 months followed by a
regression of obtained language and motor skills [7]. RTT pa-
tients usually exhibit a deceleration of head growth, respiratory
dysfunction, scoliosis, cognitive impairment, seizures and social
withdrawal [8,9]. In addition to RTT, numerous MECP2 muta-
tions have now been linked to a variety of additional disorders,
including autism, Angelman syndrome, learning disabilities and
mental retardation syndromes [7,10–14].
MeCP2 has been reported to associate with myriad protein
partners, including Sin3A [3,5], c-REST and Suv39h1 [15],
c-Ski and N-CoR (nuclear receptor co-repressor) [16], Brm [17]
and HP1 [18], all supporting a model of MeCP2 interacting
with or being a stable component of transcriptional co-repressor
complexes, resulting in targeted transcriptional repression of
methylated DNA through modification of the chromatin state or
chromatin-associated proteins. However, the biological relevance
and implications towards RTT for these numerous documented
MeCP2 interactions is not clear due in part to the particular
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methods utilized and non-neuronal choices for initial cellular
protein sources. In fact, contradicting these numerous studies, it
has been proposed that endogenous MeCP2 does not form any
stable protein–protein interactions in vivo [19]. Compounding the
issue, recent work has expanded MePC2’s proposed gene regu-
latory role beyond mere transcriptional repression; MeCP2 is
implicated in transcriptional activation, genome-wide transcrip-
tional silencing, mediating chromatin and nuclear architecture,
and regulating pre-mRNA splicing as well [20–23]. Thus the
in vivo protein–protein interaction profile of endogenous MeCP2,
particularly in the brain, is still an open question and increasingly
more important to understand as new functions for MeCP2 are
emerging.
Genetic studies in mice suggest that expression of functional
MeCP2 in neurons is essential for normal synapse formation
and neuronal function during postnatal development and re-
expression of MeCP2 in differentiated neurons alone rescues
an RTT mouse model [24–29]. However, this idea is being chal-
lenged by a recent study that indicates the lack of MeCP2 spe-
cifically in glial cells contributes to RTT phenotypic neurons
by an unknown secreted glial factor [30]. This discrepancy il-
lustrates the need for more unbiased approaches in determining
the molecular roles of MeCP2 in both normal and RTT brain;
thus, intact mammalian brain tissue would be the ideal source
to study endogenous MeCP2 protein function. In the present
study, we use the power of biochemistry to characterize MeCP2
in the mammalian brain and show that native MeCP2 protein
purified from adult rat brain exists in multiple biochemically
distinct pools/complexes, consistent with MeCP2 working as
a multi-functional protein. We further characterize one brain-
derived MeCP2 complex that contains Prpf3 (pre-mRNA pro-
cessing factor 3), a known spliceosome-associated protein [31],
as well as the Sdccag1 (serologically defined colon cancer an-
tigen 1) [32], a mediator of nuclear export [33]. MeCP2 shows
specific, direct interactions with Prpf3 and Sdccag1, and these in-
teractions are disrupted by certain RTT mutations. In addition, we
show that MeCP2 and Prpf3 co-associate in vivo with mRNAs
from genes activated by MeCP2, further supporting the previ-
ously identified regulatory role of MeCP2 in mRNA biogenesis
[23] and providing another potential mechanism disrupted during
RTT pathogenesis.
MATERIALS AND METHODS
MeCP2 protein purification
Rat brain nuclei were isolated generally as described [34]. Adult
rat brains (n = 200 per extract preparation; Pel-Freez Biologic-
als) were thawed on ice, homogenized and nuclei were collec-
ted. Nuclei were suspended in buffer A [20 mM Hepes (pH 7.5),
1.5 mM MgCl2, 1 mM EGTA, 10 % glycerol, 0.5 mM DTT (di-
thiothreitol), 1 μg/ml leupeptin, 1 μg/ml pepstatin and 1 μg/ml
aprotinin] supplemented with 350 mM NaCl (A-350) and extrac-
ted for 30 min at 4◦C. Insoluble material was removed by cent-
rifugation at 200 000 g for 20 min at 4◦C. The supernatant was
diluted with buffer A to <200 mM NaCl and used as a soluble
protein source for chromatography.
Chromatography was preformed using an AKTA-FPLC ap-
paratus (GE Healthcare) at 4◦C in buffer A with indicated con-
centrations of NaCl. Soluble protein (130 mg per purification)
was fractionated over a MonoQ10/10 column with bound protein
eluted by a 20 CV (column volume) linear salt gradient from 100
to 1000 mM NaCl, collecting 0.5 CV fractions. The MeCP2-
containing fractions peaking at 230 mM NaCl (QB1/2) were
pooled, diluted with buffer A and fractionated over MonoS5/5
with bound protein eluted by a 20 CV linear salt gradient from 250
to 1000 mM NaCl, collecting 0.5 CV fractions. The MeCP2 con-
taining fractions peaking at 550 mM NaCl (QB2) were combined
and loaded on to a 1 ml Heparin FastFlow column and eluted with
a 10 CV linear gradient from 450 to 1000 mM, collecting 0.5 CV
fractions. Pooled heparin column fractions containing MeCP2
were applied to a 110 ml Superose6 column and fractionated
in buffer A-150 with 0.1 % Triton X-100. Subsequently, 0.5 ml
of each fraction was trichloroacetic acid-precipitated, subjected
to SDS/PAGE, and used for Western blotting or silver staining.
Silver-stained polypeptide bands precisely co-fractionating with
MeCP2 (by Western blotting) were excised and analysed by MS.
For the nuclease treatment experiments, MonoQ-eluted
MeCP2 was dialysed against buffer A-100 containing 1 mM
CaCl2, 10 mM MgCl2 and without EGTA then either treated with
or without 500 units of benzonase nuclease (Sigma) for 30 min
at 37◦C, and re-tested for ability to bind the MonoQ resin.
Antibodies and Western blot analysis
Protein samples were separated by SDS/PAGE and transferred
to ECL nitrocellulose membrane (GE Healthcare) for Western
blotting by standard methods. For each experiment, the Western
blotting images presented are from the same exposure on the
same piece of film, linearly adjusted for brightness in Adobe
Photoshop. The anti-MeCP2 3998 antibody is a rabbit poly-
clonal antibody derived from bacterially expressed recombin-
ant protein encoding the full-length human MeCP2e2 isoform.
The anti-(MeCP2 7–18) antibody is a rabbit polyclonal derived
from bacterially expressed recombinant protein encoding amino
acid residues 310–388 of the human MeCP2e2 isoform. Anti-
bodies were used at the following concentrations: anti-(MeCP2
7–18), 1:2000; anti-MeCP2 (Upstate 07–013) 1:1000; anti-Prpf3
(MBL D171–3) 1:2000; and anti-HA (haemagglutinin) high
affinity (clone 3F10) at 1:1000.
Mass spectrometry
MS was carried out at the Protein Sciences Facility at the Uni-
versity of Illinois. FPLC-purified fractions were separated by
SDS/PAGE, visualized by MS-compatible silver staining. Poly-
peptide bands were excised, destained (50 % acetonitrile and
25 mM ammonium bicarbonate) and digested in 25 μl of Sequen-
cing Grade Trypsin (12.5 ng/μl in 25 mM ammonium bicarbon-
ate, G-Biosciences St Louis, MO, U.S.A.) using a CEM Discover
Microwave Digestor for 15 min at 55◦C (60W). Digested peptides
were extracted using 50 % acetonitrile with 5 % formic acid, dried
in a Savant SpeedVac apparatus and suspended in 13 μl of 5 %
acetonitrile containing 0.1 % formic acid with 10 μl of sample
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used for MS analysis. The mass spectrometer used was a Waters
quadrupole time-of-flight (Q-ToF) mass spectrometer connected
to a Waters nano-Acquity UPLC. The column used was Waters
Atlantis C18 (0.075 mm ×150 mm) with a flow rate of 250 nl/min.
Peptides were eluted using a linear gradient of water/acetonitrile
containing 0.1 % formic acid (0–60 % B) in 60 min. The mass
spectrometer was set for result-dependent acquisition; MS/MS
(tandem MS) was performed on the most abundant four peaks
at any given time. Data analysis was performed using Waters
Protein Lynx Global Server 2.2.5, Mascot (Matrix Sciences) and
BLAST against NCBI NR database.
Generation of plasmids
RNA was purified from rat brain tissue or HeLa cells using
TRIzol® Reagent (Invitrogen) as per the manufacturer’s instruc-
tions. All cDNAs were generated using SuperScript III one-
step RT (reverse transcription)–PCR with Platinum Taq (In-
vitrogen). All PCRs were performed with Phusion polymerase
(New England Biolabs) and cloned into pGEM-T easy (Pro-
mega) for sequencing before subcloning into pGEX5-X1 (GE
Life sciences), pCDNA 3.1 (Invitrogen) or the pCDNA 3.1 HA
vector [35]. All primers are listed in Supplementary Table S1
(at http://www.bioscirep.org/bsr/031/bsr0310333add.htm). All
human MeCP2 constructs were generated from the human
MECP2E2 cDNA (NM_004992). To generate constructs for
in vitro synthesized proteins, cDNAs were PCR-amplified us-
ing primers listed in Supplementary Table S1 and subcloned into
the specified restriction sites of pCDNA 3.1. Rat cDNAs were
subcloned between NotI and XhoI; the human Prpf3 cDNA clone
was subcloned between EcoRI and XhoI; the human full-length
MeCP2 was amplified from full-length cDNA and subcloned
between NotI and XhoI. Constructs for bacterially generated GST
(glutathione transferase) fusion proteins were PCR-amplified
from full-length cDNAs, subcloned into the specified restric-
tion sites of pGEX5-X1 using primers listed in Supplementary
Table S1. Rat GST–Prpf3 was subcloned between BamHI and
XhoI. The rat and human GST–MeCP2 full-length, GST–MeCP2
deletion and human GST–MeCP2 RTT cDNAs were subcloned
between EcoRI and XhoI. For the pCDNA3PHA-MECP2 vector,
full-length human MeCP2 was subcloned between NotI and XhoI
restriction sites of the pCDNA3.1 HA vector and subsequent
digestion with NdeI and XhoI for cloning of the HA–MeCP2
fragment into the pCDNA3.1P puromycin vector.
Cell culture
HT-22 cells were transfected with pCDNA 3.1P HA-MeCP2 us-
ing Fugene HD transfection reagent (Roche). Stable integrants
were selected as pools in puromycin (1 μg/ml), and maintained
in DMEM (Dulbecco’s modified Eagle’s medium; Biowhittaker)
supplemented with 10 % fetal bovine serum, glutamine, antibiot-
ics and puromycin.
GST pull-down assay
Assays were preformed essentially as previously described
[35], using recombinant GST fusion proteins and in vitro tran-
scribed/translated proteins radiolabelled with [35S]methionine
using the T7 TnT Quick Coupled Transcription/Translation Sys-
tem (Promega) with or without 250 units of Benzonase nuclease.
Co-IP (co-immunoprecipitation)
Co-IPs from fractionated brain extracts were carried out as fol-
lows: MonoQ-fractionated rat brain nuclear extracts (QB2) were
diluted to 100 mM NaCl with buffer A (0). Protein A Dyna-
beads (Invitrogen) were blocked with BSA and added to the
extracts with 10 μl of either anti-MeCP2 3998 or normal rabbit
serum IgG for 2 h at 4◦C with rotation. Co-immunoprecipitates
were washed three times with buffer A225, eluted by boiling
in Laemmli buffer, separated by SDS/PAGE and subjected to
Western-blot analysis. Co-IPs from cell culture were carried out
as previously described [23] with modifications. Confluent 10-cm
plates of HT-22 cells stably expressing HA–MeCP2 were lysed
in 1 ml of IPH buffer [50 mM Tris/HCl (pH 8.0), 150 mM NaCl,
5 mM EGTA, 0.5 % Igepal and 1 mM PMSF] and debris re-
moved by centrifugation. Lysates were pre-cleared with Protein
A agarose, then incubated for 4 h with anti-HA (Sigma, E6779)
or irrelevant IgG with Protein A agarose beads (Santa Cruz Bio-
technologies) at 4◦C with rotation. Nuclease treatment was pre-
formed by suspension of protein-bound beads with 125 units of
benzonase in the manufacturer’s recommended buffer for 10 min
at 37◦C. IPs were washed three times with IPH buffer, eluted
with Laemmli buffer, separated by SDS/PAGE and subjected to
Western-blot analysis.
RIP (RNA IP) and Re-RIP
Experiments were performed as previously described with slight
modifications [36]. HT-22 cells (108) stably expressing HA–
MeCP2 were collected, washed and suspended in 4 ml of
PBS. Cross-linking buffer (50 mM Hepes, 100 mM NaCl, 1 mM
EDTA, 0.5 mM EGTA and 11 % formaldehyde) was added
(400 μl), incubated at room temperature (23◦C) for 30 min with
rocking and quenched for 5 min at room temperature. Cell pellets
were washed with PBS and lysed in 1 ml of FA buffer [50 mM
Hepes/KOH (pH 7.5), 140 mM NaCl, 1 mM EDTA, 1 % Triton
X-100, 0.1 % sodium deoxycholate and protease inhibitors] by
sonication. The lysed cells were treated with 200 units of DNase
I (Promega) in 25 mM MgCl2, 5 mM CaCl2 and 6 μl of RNasin
(Promega) for 30 min at 37 ◦C, cleared by centrifugation at 4◦C,
diluted 1:10 with ChIP (chromatin immunoprecipitation) dilution
buffer [50 mM Hepes (pH 7.5), 140 mM NaCl, 1 mM EDTA,
10 % glycerol and 0.5 % Nonidet P40] and incubated with either
anti-HA antibody or non-specific IgG with 4 μl of RNasin, for
12 h, rotating at 4◦C. Protein A or G Dynabeads were added for
1 h rotating at 4◦C and washed three times for 10 min each
with wash buffer [50 mM Tris/HCl (pH 7.4), 500 mM NaCl,
1 % Triton X-100 and 0.1 % SDS]. For Re-RIP experiments,
beads were washed and bound immune-RNA complexes were
released in 20 mM DTT for 30 min at 37◦C and resuspended
in 1 vol. of ChIP dilution buffer for Re-RIP with antibody for
Prpf3 and washed as described above. Beads were brought up
in 200 μl of elution buffer [50 mM Tris/HCl (pH 7.4), 200 mM
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Figure 1 Brain-derived nuclear MeCP2 exists in multiple biochemically distinct pools
(A) Chromatographic separation of crude rat brain nuclear extract by strong anion exchange (MonoQ resin) results in three
distinct pools of MeCP2 as indicated by Western-blot analysis using the MeCP2 7–18 antibody (Figure S1). The majority
of MeCP2 does not bind the column (QF), whereas the bound MeCP2 elutes in two peaks, at 230 mM NaCl (QB1/2)
and 450 mM NaCl (QB3). (B) MonoQ-resin-bound fractions of MeCP2 were treated with (+) or without (No) benzonase
nuclease and tested for ability to re-bind the Mono Q. Western-blot analysis for MeCP2 of MonoQ flow through, wash, and
1000 mM NaCl step elution shows that benzonase treatment does not affect binding of MeCP2 to the Mono Q column. (C)
Plasmid spiked MonoQ fractions treated with benzonase (+) or untreated ( − ) in parallel served as controls for benzonase
treatment.
NaCl and 20 μg of proteinase K] for 1 h at 42◦C, and cross-links
reversed at 65◦C. Samples were extracted with acid-equilibrated
(pH 4.8) phenol/chloroform (5:1, v/v) and ethanol-precipitated.
Precipitated material was suspended in 50 μl of DEPC (diethyl
pyrocarbonate)-treated water and used for RT–PCR analysis with
SuperScript III One-Step RT–PCR with Platinum Taq (Invitro-
gen) for mouse Cdk10 (cyclin-dependent kinase 10) and Frg1.
Reaction mixtures were analysed by electrophoresis on a 2 %
agarose gel.
RESULTS
MeCP2 exists in at least four distinct protein pools
in rat brain nuclei
A large-scale biochemical purification of endogenous MeCP2
protein from rat brain nuclear extract was performed to char-
acterize the native MeCP2 in the mammalian brain. Whole rat
brains were homogenized under non-denaturing conditions, the
intact nuclei were purified by centrifugation through a sucrose
cushion, and nuclear proteins were extracted under mild ionic
conditions. Proteins were initially fractionated by strong anion
exchange (MonoQ) column chromatography with the MeCP2
protein being tracked by Western blotting with multiple MeCP2-
specific antibodies (Figure 1A and Supplementary Figure S1 at
http://www.bioscirep.org/bsr/031/bsr0310333add.htm; and res-
ults not shown), all providing virtually identical profiles. The
majority of soluble MeCP2 protein (∼90 %) did not associate
with the MonoQ resin agreeing with a previous report [19]; how-
ever, a significant fraction (∼10 %) of this brain-derived MeCP2
consistently bound to MonoQ resin and was eluted in two dis-
tinct peaks along the linear salt gradient (Figure 1A), indicating
multiple biochemically distinct pools of MeCP2.
The MonoQ bound (QB) MeCP2 elution profile showed an ini-
tial broad peak (QB1/2) concentrated at 230 mM NaCl and tailing
to 370 mM, suggesting multiple MeCP2 complexes, with a minor
yet distinct peak (QB3) centred at 450 mM NaCl (Figure 1A).
Since MeCP2 is a DNA-binding protein and also known to inter-
act with RNA, the potential of nucleic acids mediating the anionic
association of MeCP2 with the cationic resin was addressed. The
QB fractions were treated with benzonase nuclease to remove
both DNA and RNA and then MonoQ chromatography was re-
peated. We found that all of the nuclease-treated QB MeCP2
still bound the MonoQ resin and was released by step elution,
indicating the interaction was both RNA and DNA independ-
ent (Figures 1B and 1C). Finally, the presence of MeCP2 in the
MonoQ flow through (QF) and each elution peak (QB1/2 and
QB3) was subsequently confirmed by MS (Supplementary Fig-
ure S2 at http://www.bioscirep.org/bsr/031/bsr0310333add.htm).
The early eluting MonoQ-bound pool of MeCP2 (QB1/2) was
characterized further for complexity and content (Figure 1A).
The QB1/2 peak fractions were pooled and fractionated over the
MonoS strong cation exchange resin, resolving into two peaks
of MeCP2 protein (Figure 2D, top panel), the first being eluted
at 400 mM NaCl (QB1) and the second being eluted at 550 mM
NaCl (QB2). These results indicate at least three biochemically
distinct pools of MeCP2 exist in the initial QB fraction and four
MeCP2 pools exist overall in rat brain nuclear extract (QF and
QB1, QB2 and QB3).
Brain-derived MeCP2 exists in a complex with the
splicing factor Prpf3
To identify potential MeCP2-interacting proteins, the more
abundant MonoS-bound pool of MeCP2 (QB2) was purified fur-
ther by fractionation using heparin affinity chromatography and
gel filtration through Superose6 (Figure 2A). Western blotting
and silver-stain analysis of the final fractionation showed MeCP2
peaking with an apparent molecular mass of 600–700 kDa and
precisely co-purifying with six additional polypeptides (Fig-
ures 2B and 3). Since monomeric MeCP2 has previously been
shown to exhibit an unusual Superose6 gel filtration profile mi-
grating equivalent with an apparent mass of approx. 450 kDa
[19], the apparent mass for QB2 MeCP2 is consistent with it
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Figure 2 The QB2 pool of MeCP2 co-purifies with six candidate proteins including Prpf3
(A) MeCP2 peak fractions were purified using a four-step process including the MonoQ strong anion exchange resin, MonoS
strong cation exchange resin, Heparin affinity resin and by Superose6 gel filtration. (B) (Upper panel) Silver-stain analysis
of the Superose6 fractionation of the QB2 MeCP2 pool. (Lower panel) Western-blot analysis of Superose6 fractions shows
MeCP2 protein peaks in fractions 7 and 8, precisely co-fractionating with Prpf3 protein. (C) The MonoQ fractionation of
brain-derived nuclear extract reveals an overlap of Prpf3 and MeCP2 yet pools of each protein do not co-fractionate and
remain independent of the other. (D) Peak fractions of the QB1/2 fractionated over the MonoS resin show two distinct
pools of MeCP2 peaking at 400 mM NaCl (QB1) and 550 mM NaCl (QB2) by Western-blot analysis. Corresponding MonoS
fractions probed for Prpf3 protein shows precise co-fractionation with QB2 Mecp2.
being associated with additional proteins. Therefore all six
MeCP2 co-purifying polypeptides were identified by MS with
significant coverage (Figure 3 and Supplementary Figure S3 at
http://www.bioscirep.org/bsr/031/bsr0310333add.htm) as Prpf3,
Sdccag1, ATP-binding cassette 50 and three components of a
translation initiation complex (Eif2 subunits 1, 2 and 3). Since
a commercial antibody was available against Prpf3, Western-
blot analysis of the size exclusion chromatography fractions was
carried out and showed that MeCP2 and Prpf3 precisely co-
fractionate (Figure 2B, bottom) confirming the silver-stain ana-
lysis (Figure 2B, top).
With Prpf3 identified as a putative MeCP2-interacting protein,
the MeCP2 fractionation scheme (Figure 2A) was analysed for
Prpf3 by Western blotting to determine whether Prpf3 was present
in all MeCP2 pools or specific to QB2 and similarly to determ-
ine whether all Prpf3 in brain extracts associated with MeCP2.
Not surprisingly, only a fraction of Prpf3 in brain extracts co-
fractionated with MeCP2 when assaying the MonoQ separation
profile (Figure 2C); however, all of the detectable Prpf3 over-
lapping with MeCP2 specifically co-fractionated with the QB2
pool of MeCP2 from the MonoS fractionation and not with the
QB1 MeCP2 pool (Figure 2D). Thus Prpf3 distinguished QB2
from other MeCP2 protein pools. Because Prpf3 is a known com-
ponent of the spliceosome [31] and MeCP2 has been shown to
interact with another spliceosome-associated protein, YB-1 [23],
the QB2 fractionation was screened for YB-1. However, YB-1
was not found by Western blotting and YB-1 was absent from the
MS analysis indicating YB-1 did not co-purify with QB2 MeCP2
under these conditions (Figure 3, and results not shown).
To confirm that native MeCP2 and Prpf3 are in a complex
in vivo, co-IP experiments were performed (Figure 4). In brain ex-
tracts, as determined by the biochemical fractionations described
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Figure 3 Identification of candidate MeCP2 complex proteins
(A) Polypeptides from silver-stained Superose6 fractions were excised and identified by LC (liquid chromatography)-MS/MS.
MeCP2 and two other nuclear proteins, Sdccag1 and Prpf3, were identified as well as components of a translation initiation
complex. (B) MS peptides identifying MeCP2, Prpf3 and Sdccag1.
Figure 4 Co-IPs confirmed MeCP2 associates with Prpf3 in vivo
(A) Western blotting of a co-IP experiment from fractionated brain extract showing a peak MeCP2 fraction (lane 1, 5 % input),
control IgG IP (lane 2), anti-MeCP2 IP (lane 3) and anti-MeCP2 IP treated with benzonase (benz) (lane 4) demonstrates
that Prpf3 interacts with MeCP2 in the brain independent of nucleic acids. (B) Western blotting of a co-IP experiment
from HA–MeCP2 transfected HT-22 cells showing whole-cell extract (lane 1, 5 % input), IgG IP (lane 2), anti-HA IP (lane 3)
and anti-HA IP treated with benzonase (lane 4) demonstrates that Prpf3 interacts with MeCP2 cell culture independent of
nucleic acids.
above, the vast majority of MeCP2 is not associated with Prpf3
and likewise the majority of Prpf3 in brain is not associated with
MeCP2 making it difficult to visualize any interaction by co-IP
directly from crude nuclear extracts. Thus two approaches were
used: co-IPs from fractionated brain nuclear extract (Figure 4A)
and co-IPs from crude extracts using tissue culture cells overex-
pressing an epitope-tagged version of MeCP2 (Figure 4B). Rat
brain nuclear extract was prepared and fractionated over MonoQ
as described above. The QB1/2 MeCP2 fractions were diluted
to 100 mM NaCl in buffer A (0) and used for co-IP experiments
assayed by Western blotting. Using the anti-MeCP2 3998 anti-
body to IP, Prpf3 was specifically co-immunoprecipitated from
these fractions and the interaction between MeCP2 and Prpf3
was not dependent on nucleic acids (Figure 4A, lanes 3 and
4). Alternatively, to show co-IP interaction between MeCP2 and
Prpf3 from crude cell extracts, the murine hippocampal HT-22
cell line was used to generate a pool of cells stably expressing
HA epitope-tagged human MeCP2. Immunofluorescence showed
that HA–MeCP2 in these cell lines predominantly concentrated
to DAPI (4′,6-diamidino-2-phenylindole)-rich heterochromatic
foci as expected for endogenous MeCP2 (supplemetnary Fig-
ure S4 at http://www.bioscirep.org/bsr/031/bsr0310333add.htm).
Anti-HA antibodies were then used to specifically co-IP HA–
MeCP2 and MeCP2-associated proteins from these cell lines.
Western blotting showed that HA–MeCP2 specifically co-
immunoprecipitated a fraction of the endogenous mouse Prpf3
(Figure 4B, lane 3), indicating that Prpf3 and MeCP2 exist in a
stable complex within these neuronal cells, and their interaction
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Figure 5 MeCP2 directly interacts with Prpf3 and Sdccag1
For all experiments, the GST-tagged protein was bacterially generated and purified and the visualized
[35S]methionine-labelled interacting proteins were generated by in vitro transcription and translation. Coomassie
Brilliant Blue staining of the gels showing input GST fusion proteins are shown in Supplementary Figure S4 at
http://www.bioscirep.org/bsr/031/bsr0310333add.htm. (A) Prpf3 (left) and Sdccag1 (middle) interact directly with
GST-tagged MeCP2 but not GST alone. Eif2s3 (right) does not interact with either GST–MeCP2 or GST–Prpf3. Benzonase
treatment indicates these interactions are independent of nucleic acids. (B) Reciprocally, MeCP2 interacts with GST-tagged
Prpf3 independent of nucleic acids. (C) GST–MeCP2 deletion constructs mapped the region of MeCP2 required for the
direct interactions with Prpf3 or Sdccag1 in vitro. (D) GST-tagged MeCP2 containing the indicated RTT non-sense mutations
disrupt Prpf3 binding if truncations are before amino acid 104, but identify a second Prpf3-binding site on MeCP2 in the
MBD between amino acids 104 and 141. All RTT truncations tested abolished Sdccag1 binding to MeCP2. (E) Map of
MeCP2e2 protein showing the Prpf3 and Sdccag1 interaction domains with boundary amino acid numbers. The MBD, TRD
and RNA-binding domain (*) [37] are indicated.
was not dependent on nucleic acids (Figure 4B, lane 4). We con-
clude that MeCP2 and Prpf3 associate in vivo.
MeCP2 interacts directly with Prpf3 and Sdccag1,
independent of nucleic acids
To investigate which of the co-purifying candidate proteins dir-
ectly interacted with MeCP2, the cDNAs for each identified pro-
tein was cloned and the recombinant proteins were tested for
the ability to interact with MeCP2 in vitro (Figure 5 and Supple-
mentary Figure S4). GST pull-down assays using a GST–MeCP2
fusion protein showed that rat Prpf3 specifically interacted with
full-length rat MeCP2, but not GST alone (Figure 5A, left panel),
and reciprocally rat GST–Prpf3 interacted with rat MeCP2
(Figure 5B). Furthermore, treatment of the GST–MeCP2/Prpf3
reaction with benzonase nuclease showed the interaction was not
dependent on nucleic acids (Figure 5A and 5B). Similarly, rat
Sdccag1 specifically interacted with rat GST–MeCP2 in a nuc-
leic acid-independent manner (Figure 5A, middle panel). Inter-
estingly, neither rat GST–MeCP2 nor rat GST–Prpf3 interacted
with any of the other four identified polypeptides supporting the
specificity of the observed interactions of MeCP2, Prpf3 and
Sdccag1 (Figure 5A, right panel, and results not shown).
Mapping the Prpf3 and Sdccag1 interaction
domains of MeCP2
The regions of MeCP2 that directly interact with Prpf3 and Sd-
ccag1 were mapped by GST pull-down analysis. A series of bac-
terially generated human GST–MeCP2 deletion mutants were
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tested for their ability to interact with in vitro synthesized human
Prpf3 (Figures 5C and 5D). Prpf3 retained the ability to inter-
act with MeCP2 N-terminal deletions up to and including amino
acid residue 195 as well as a C-terminal deletion lacking amino
acid residues 309–486. However, Prpf3 did not interact with an
MeCP2 deletion lacking amino acid residues 1–308, indicating
that the TRD (transcription repression domain) region is required
for interaction (Figure 5C, upper panel). Therefore a fragment of
MeCP2 that contains only amino acid residues 207–308, corres-
ponding to the TRD domain, was tested and found to interact
with Prpf3 with similar apparent affinity as full-length MeCP2.
Similarly, Sdccag1 was synthesized in vitro and subjected to
the same series of GST–MeCP2 deletions as Prpf3 (Figure 5C,
lower panel). Sdccag1 was capable of interacting with all of the
N-terminal MeCP2 deletion proteins tested, but failed to inter-
act with a MeCP2 deletion lacking the region C-terminal to the
TRD. Thus the interaction domain with Sdccag1 resides between
amino acid residues 309 and 486, adjacent with the Prpf3 inter-
action domain (Figure 5E).
Considering most known RTT mutations reside in MECP2 and
many are nonsense mutations resulting in a truncated MeCP2, it
is likely that some of these mutations would also disrupt the in-
teractions of Prpf3 and/or Sdccag1 with MeCP2. A series of bac-
terially generated human GST–MeCP2 RTT nonsense mutants
were produced and tested for their ability to interact with in vitro
synthesized human Prpf3 and rat Sdccag1 (Figure 5D). The series
of RTT mutations truncate MeCP2 ranging from amino acids 49
to 204. All of these RTT nonsense mutants lack the C-terminal
region of MeCP2 and therefore disrupted its interaction with
Sdccag1 as expected (Figure 5D, bottom panel). The Prpf3 inter-
action was disrupted by RTT truncations at amino acids S49X,
S68X and W104X as well. However, the Prpf3 interaction with
MeCP2 was maintained with the RTT truncations Y141X, R168X
and S204X. This indicates there are two MeCP2 regions cap-
able of interacting with Prpf3 flanking the inter-domain region
between the MBD and TRD of MeCP2. Interestingly, this same
inter-domain region of MeCP2 has been previously characterized
as the RG domain and is required for MeCP2’s RNA-binding
activity [37]. We conclude that MeCP2 contains two domains
sufficient for interaction with Prpf3, one in the MBD between
amino acids 104 and 141, and the second in the TRD between
amino acids 207 and 294 and one domain for MeCP2’s interac-
tion with Sdccag1, residing between amino acids 311 and 486
(Figure 5E). Therefore any RTT mutation truncating MeCP2 at or
before amino acid residue 104 will abolish the Prpf3 and Sdccag1
interaction, whereas any RTT truncation at or before amino acid
residue 297 would disrupt the Sdccag1 interaction with MeCP2,
all of which could affect MeCP2’s role in RNA biogenesis.
MeCP2 interacts with mRNA in vivo
Several lines of evidence suggest that MeCP2 is associated with
mRNA biogenesis; MeCP2 binds RNA in vitro [37], is part of
an RNP complex with YB-1 in cell culture [23], MeCP2 knock-
out mice show mis-spliced transcripts in the brain [23], it has
been identified as a transcriptional activator at the majority of
gene promoters it has been shown to regulate [21], and in the
present study MeCP2 was shown to interact with the splicing
factor Prpf3. To determine whether MeCP2 interacts with the
RNA transcripts expressed from the genes it regulates in vivo,
RIPs were performed. Using anti-HA antibodies on HT-22 (HA–
MeCP2) cell lysates, mRNAs for the MeCP2-regulated genes
Cdk10 and Frg1 were capable of being specifically RNA immun-
oprecipitated (Figure 6A). Assaying the IPs by RT–PCRs using
oligonucleotide primers designed to amplify across exon junc-
tions of Cdk10 and Frg1 show that MeCP2 is associated with the
spliced form of the genes, whereas MeCP2 is not associated with
the Casc3 gene transcript (Figure 6A), a gene not regulated by
MeCP2 [21], supporting the specificity of the MeCP2–mRNA in-
teraction. The RIPs were RNase sensitive confirming that RNA,
and not DNA, was specifically immunoprecipitated. Interestingly,
RT–PCR for RIPs using primers for Cdk10 additionally show
what appears to be pre-mRNA by size and RNase sensitivity
(Figure 6A, top). Although the Cdk10 pre-mRNA product was
not observed in 100 % of the RT–PCR analyses for Cdk10, it was
observed repeatedly and suggests that MeCP2 associates with
the Cdk10 RNA at a step before the completion of splicing and
remains bound after RNA processing is completed.
To investigate whether Prpf3 was part of the HA–MeCP2–
mRNA complex, an RIP and Re-RIP approach was implemen-
ted. Anti-HA antibodies were used to RNA immunoprecipitate
HA–MeCP2–mRNA complexes from HT-22 (HA–MeCP2) cell
lysates, the bound complexes were eluted from the HA antibodies
intact using DTT to disrupt the IgG structure and then anti-Prpf3
antibodies were used to Re-RIP. Therefore any RNAs present
in the Re-RIP must have been associated with both MeCP2 and
Prpf3. RT–PCR analysis showed that RIP for HA–MeCP2 and
subsequent Re-RIP for Prpf3 protein immunoprecipitated mRNA
for Cdk10, indicating that both proteins are in fact associated with
this target mRNA (Figure 6B), further supporting their being in
a complex in vivo.
DISCUSSION
MeCP2 has been characterized as a multifunctional protein us-
ing a variety of techniques and from numerous cellular contexts;
however, only the biochemical characteristics of the endogen-
ous MeCP2 protein in the mammalian brain are relevant to RTT.
MeCP2 mutations identified from RTT patients are generally
point mutations resulting in a single missense or non-sense amino
acid change, and have been identified throughout all protein
domains of MECP2 (http://www.rettsyndrome.org/), suggesting
that all domains are critical for MeCP2 function [38]. Although
all these mutations produce clinical RTT pathology, certain muta-
tions are more strongly associated with particular symptoms and
disease severity suggesting that all RTT mutations in MECP2
are not equal, with some potentially being more disruptive to-
wards MeCP2’s many functions [39]. The underlying mechan-
isms of how these myriad mutations lead to RTT pathophysiology
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Figure 6 The MeCP2–Prpf3 complex interacts with mRNA in vivo
(A) RT–PCR analysis of a RIP from HA–MeCP2 stably transfected HT-22 cells indicates an association of HA–MeCP2 with
Cdk10 mRNA (top, lane 2) and FRG1 mRNA (middle, lane 2), but not Casc3 mRNA (bottom, lane 2). Control RIPs using
normal rabbit serum (IgG) (lane 3) show no RT–PCR product. RT–PCRs using unbound RNA from RIPs indicate target
mRNAs were present in all RIP samples (lanes 4 and 5) and all RT–PCRs were RNase sensitive (+RNase) confirming RNA
and not DNA was being assayed. (B) An anti-HA RIP followed by anti-Prpf3 Re-RIP experiment from HA–MeCP2 HT-22 cells
was assayed for Cdk10 mRNA by RT–PCR (lane 2). Control RIP and Re-RIP experiments using normal rabbit serum (IgG)
showed no product by RT–PCR (lane 3). Unbound mRNA was assayed by RT–PCR for the RIP (lanes 6 and 7) and Re-RIPs
(lanes 4 and 5) to confirm the presence of the Cdk10 mRNA in the reaction mixtures. All RT–PCRs were sensitive to RNase
treatment (lower panel) confirming the amplifications were from RNA and not DNA templates.
remain unclear due to a lack of understanding towards the com-
plete scope of MeCP2’s normal function in the brain. In the
present study, we identified four distinct brain-derived MeCP2
protein pools, agreeing with the functional results proposing
multiple roles for MeCP2 [38]. Characterizing one complex as
containing MeCP2, Pprf3, Sdccag1 and mRNA strongly com-
plements previously published results that MeCP2 is an RNA-
binding protein involved in mRNA splicing [23].
MeCP2’s association with Prpf3, a major component of the
spliceosome, supports MeCP2 as having a role in modulating
mRNA splicing [23]; however, it is not clear what exactly that
role might be. MeCP2 is present at the promoter of many act-
ively transcribed genes [20], and activates a majority of genes it
regulates in the mouse hippocampus [21]. Interestingly, a recent
study suggests that differential gene body methylation may play
a role in RNA transcript splicing [40]. Genome-wide methyla-
tion profiling in multiple human cell types found that exons were
more highly methylated than introns, and that there were sharp
transitions of DNA methylation at exon–intron boundaries [40].
Experimentally, it is known that MeCP2 binds RNA in vitro with
an affinity similar to that of methylated DNA, and that the two
activities are mutually exclusive [37]. Thus MeCP2 at an active
promoter or within the body of a transcribed gene would be well
positioned spatially on its release to interact with the transcripts
of the genes it activates and influence splice site selection. There-
fore it is reasonable to propose that MeCP2-activated genes would
also be targets for splicing regulation by an MeCP2 containing
complex. Supporting this model, RNA transcripts from Cdk10, a
gene positively regulated by MeCP2 binding at its promoter [21]
and abnormally spliced in Mecp2308Y mice [23], were associated
with both MeCP2 and Prpf3 in vivo (Figure 6).
Based on what is known about MeCP2 and Prpf3 independ-
ently, it is possible that the direct interaction of MeCP2 with Prpf3
could function in splice site selection. Prpf3 is one of multiple
associated proteins of the U4/U6.U5 tri-snRNP (tri-small nuclear
ribonucleoprotein) complex that is recruited to the splice site to
form and stabilize the functional spliceosome, and is essential
for pre-mRNA splicing [31,41]. Importantly, MeCP2 can bind
RNA directly [37] and has been implicated as a regulator of al-
ternative splicing in the HeLa and Neuro2A cell lines through an
RNA-dependent interaction with YB-1 [23], a protein known to
participate in splicing of mRNAs [42]. Although we were unable
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to detect YB-1 as a component of the MeCP2–Prpf3–Sdccag1
complex in brain, it is inefficient to inhibit the highly active and
stable RNases that would abolish any YB-1–RNA–MeCP2 in-
teraction during purification, hence we cannot rule out that YB-1
could be part of a larger RNA-dependent alternative splicing
complex. Nevertheless, a direct interaction of MeCP2 and Prpf3
further supports a role for MeCP2 in mRNA splicing regulation.
Notably, Mecp2308/Y mice, which produce a truncated form of
MeCP2 and reproduce many of the classical features of RTT
[43], have been shown to have multiple genes that are abnormally
spliced in the brain [23]. This suggests the C-terminal portion
of MeCP2, which we have identified as the putative Sdccag1
interaction domain, plays a critical role in regulating alternative
splicing.
Sdccag1 was originally identified from colon cancer patients
by a serological analysis of recombinant cDNA expression lib-
raries (SEREX) [32] and later identified as a tumour suppressor
by its ability to cause cell cycle arrest in a non-small-cell lung
cancer cell line [44]. The significance of finding Sdccag1 as
part of the MeCP2–Prpf3 complex can only be implied due to the
limited information on its function in vertebrates and Drosophila.
Bioinformatically the Sdccag1 protein contains a predicted RNA-
binding domain homologous with a eukaryotic small nuclear
RNP [45], suggesting the capacity to function in mRNA splicing.
Functionally, the Drosophila Sdccag1 homologue Caliban has
been shown to interact with and mediate the nuclear export of the
Prospero homeodomain transcription factor (Prox in mammals)
and this interaction and function is conserved in mammalian cells
[33]. This raises the possibility that the MeCP2–Prpf3–Sdccag1
complex may not only be involved in splicing mRNA but also
transporting mRNAs. Consistent with this model, MeCP2 has
been shown to have both a nuclear and cytoplasmic localization
in neuronal cell lines [46].
Considering the range of mutations throughout MECP2 in
RTT, it is not surprising that many RTT mutations are within, or
predicted to affect both the Prpf3- and Sdccag1-binding domains,
disrupting the MeCP2–Prpf3–Sdccag1 complex and presum-
ably MeCP2-mediated splicing regulation and mRNA transport.
With MeCP2 emerging as a multifunctional protein and its biolo-
gical role in RTT unclear, identifying biochemically distinct pools
of MeCP2 in the brain containing novel MeCP2-interacting pro-
teins is a valuable tool towards an understanding MeCP2 function
and its dysfunction in RTT. The present study adds to the mount-
ing evidence indicating that one such critical function of MeCP2
in the brain involves RNA biogenesis.
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Figure S1 Anti-MeCP2 antibodies react specifically with MeCP2 from multiple protein sources
Antibodies against MeCP2 were used in Western blotting of brain nuclear extracts from cow, mouse and rat, and nuclear
extracts from human lymphoblasts expressing the RTT R168X truncation to show their specificities. Anti-MeCP2 3998
(left-hand panel) [1] and anti-(MeCP2 7–18) (centre panel) antibodies generated by ourselves were compared with an
anti-MeCP2 antibody purchased from Upstate Biotech (right-hand panel). All three antibodies react with a single polypeptide
migrating at ∼80 kDa, consistent with MeCP2s known migration on SDS/PAGE, in brain nuclear extracts (2 or 20 μg/lane)
from cow, mouse and rat. These antibodies show no reactivity to any polypeptides in the human MeCP2 RTT R168X
extracts by Western-blot analysis. These results confirm that the anti-MeCP2 7–17 antibody used in this study is specific
for MeCP2. Load controls using an antibody for Sin3A [2] are shown above.
1 To whom correspondence should be addressed (email pjones@bbri.org).
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Figure S2 MS MeCP2 peptide identifications
MS identified peptides (in red) are shown in the predicted amino acid sequences for rat MeCP2 from the QF, QB2 and QB3
pools of MeCP2.
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Figure S3 MS identifications of MeCP2 co-purifying peptides
MS identified peptides (in red) for the MeCP2 co-purifying polypeptides from the QB2 pool of MeCP2.
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Figure S4 GST input control gels
Coomassie Brilliant Blue stained SDS/PAGE gels from GST pull-down experiments show equivalent levels of GST-fusion
proteins in each pull-down reaction. (A) GST-fusion proteins from Figure 4(C) of the main paper, Prpf3. (B) GST-fusion
proteins from Figure 4(C) of the main paper, Sdccag1. (C) GST-fusion proteins from Figure 6(A) of the main paper, Prpf3.
(D) GST-fusion proteins from Figure 6(A) of the main paper, Sdccag1.
Figure S5 Characterization of HA–MeCP2 expressing HT22 cells
HT22 hippocampal neuronal cells stably transected with HA–MeCP2, visualized by (A) DAPI (4′,6-diamidino-2-phenylidole)
staining and (B) indirect immunofluorescence for HA–MeCP2 with (C) images merged, show HA–MeCP2 localizes to
heterochromatic foci.
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Table 1 PCR and RT–PCR oligonucleotide primers
Primer Plasmid construct Sequence (5′→3′)
1 pGEM ratAbcf1 ATGCCGAAGGGTCCCAAGCAGC
2 pGEM ratAbcf1 TCAATCCCGAGGTCGGTTGAC
3 pGEM ratEif2s1 ATGCCGGGTCTAAGTTGTAGATTTTATCAACAC
4 pGEM ratEif2s1 TTAATCTTCAGCTTTGGCTTCCATTTCTTCTGC
5 pGEM ratEif2s2 ATGTCCGGGGACGAGATGATTTTTGATCCTAC
6 pGEM ratEif2s2 TTAGTTAGCTTTGGCACGGAGCTG
7 pGEM ratEif2s3 ATGGCTGGGGGTGAGGCTG
8 pGEM ratEif2s3 TCAGTCATCATCTACAGTCGGCTTAATG
9 pGEM ratMeCP2 ATGGTAGCTGGGATGTTAGGGC
10 pGEM ratMeCP2 TCAGCTAACTCTCTCGGTCACG
11 pGEM ratPrpf3 ATGGCACTGTCTAAGCGGGAACTGGATG
12 pGEM ratPrpf3 CTACAGAGAACATGGCGCGTGA
13 pGEM ratSdccag1 ATGAAGACCCGCTTCAGCACTGTTGAC
14 pGEM ratSdccag1 CTATTTTCTTTTTACGTGCAGAAGATTGGG
15 pGEM human Prpf3 ATGGCACTGTCAAAGAGGGAGC
16 pGEM human Prpf3 TCAATCAGTGGACTCTAAC
17 pCDNA3.1 ratAbcf1 GCGGCCGCATGCCGAAGGGTCC
18 pCDNA3.1 ratAbcf1 CGCTCGAGTCAATCCCGAGGTCGG
19 pCDNA3.1 ratEif2s1 GCGGCCGCATGCCGGGTCTAAG
20 pCDNA3.1 ratEif2s1 CGCTCGAGTTAATCTTCAGCTTTGGCTTC
21 pCDNA3.1 ratEif2s2 GCGGCCGCATGTCCGGGGAC
22 pCDNA3.1 ratEif2s2 CGCTCGAGTTAGTTAGCTTTGGCACG
23 pCDNA3.1 ratEif2s3 GCGGCCGCATGGCTGGGGGTG
24 pCDNA3.1 ratEif2s3 CGCTCGAGTCAGTCATCATCTACAGTCG
25 pCDNA3.1 ratMeCP2 GCGGCCGCATGGTAGCTGGGATG
26 pCDNA3.1 ratMeCP2 CGCTCGAGTCAGCTAACTCTCTCGGTC
27 pCDNA3.1HA humanMeCP2 GCGGCCGCATGGTAGCTGGGATG
28 pCNA3.1HA humanMeCP2 CGCTCGAGTCAGCTAACTCTCTCGGTC
29 pCDNA3.1 ratPrpf3 GCGGCCGCATGGCACTGTCTAAGC
30 pCDNA3.1 ratPrpf3 CGCTCGAGTCACGCGCCATGTTCTC
31 pCDNA3.1 ratSdccag1 GCGGCCGCATGAAGAGCCGCT
32 pCDNA3.1 ratSdccag1 CGCTCGAGCTATTTCCTTTTTACGTTCAGAAG
33 pCDNA3.1 humanPrpf3 AGAATTCATGGCACTGTCAAAGAG
34 pCDNA3.1 humanPrpf3 CTCGAGTCAATCAGTGGACTCTAAC
35 pGEX5X ratPrpf3 AGAATTCATGGCACTGTCTAAGC
36 pGEX5X ratPrpf3 CTCGAGTCACGCGCCATGTTCTC
37 pGEX5X MeCP2 d1 AGAATTCGCCTCCCCCAAACAG
38 pGEX5X MeCP2 d1 CTCGAGTCAGCTAACTCTCTCGG
39 pGEX5X MeCP2 d2 AGAATTCAAGCAAAGGAAATCTGGC
40 pGEX5X MeCP2 d2 CTCGAGTCAGCTAACTCTCTCGG
41 pGEX5X MeCP2 d3 AGAATTCGGCACCACGAGACC
42 pGEX5X MeCP2 d3 CTCGAGTCAGCTAACTCTCTCGG
43 pGEX5X MeCP2 d4 AGAATTCACGGTCAGCATCGAG
44 pGEX5X MeCP2 d4 CTCGAGTCAGCTAACTCTCTCGG
45 pGEX5X MeCP2 d5 AGAATTCATGGTAGCTGGGATGTTAG
46 pGEX5X MeCP2 d5 CTCGAGGGTCTTGCGCTTCTTG
47 pGEX5X MeCP2 d6 AGAATTCGGCACCACGAGACC
48 pGEX5X MeCP2 d6 CTCGAGACCGAGGGTGGACAC
49 RT–PCR mouseFRG1 5′ AATTGCCCTGAAGTCTGGCTATGG
50 RT–PCR mouseFRG1 3′ CTTTCAATTTGGCTCTCCTGTCCAG
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Table 2 Continued
Primer Plasmid construct Sequence (5′→3′)
51 RT–PCR mouseCDK10 5′ GGCCAGGGATACCCAGACAG
52 RT–PCR mouseCDK10 3′ CCTCCGAGAAGGGTGTTGGC
53 RT–PCR mouseCasc3 5′ CTACAGTGAAGAGGAGAATTCCAAGGTG
54 RT–PCR mouseCasc3 3′ GATCCTCATCGTCATCCAAGTGC
55 pGEX5X MeCP2 S49X AGAATTCGCCTCCCCCAAACAG
56 pGEX5X MeCP2 S49X ACTCGAGTCATGGCTGCACGGGC
57 pGEX5X MeCP2 S68X AGAATTCGCCTCCCCCAAACAG
58 pGEX5X MeCP2 S68X ACTCGAGTCACCCTTCTGATGTCTC
59 pGEX5X MeCP2 W104X AGAATTCGCCTCCCCCAAACAG
60 pGEX5X MeCP2 W104X ACTCGAGTCAGCCTTCAGGCAGG
61 pGEX5X MeCP2 Y141X AGAATTCGCCTCCCCCAAACAG
62 pGEX5X MeCP2 Y141X ACTCGAGTCACGCAATCAACTCC
63 pGEX5X MeCP2 R168X AGAATTCGCCTCCCCCAAACAG
64 pGEX5X MeCP2 R168X ACTCGAGTCATCATCTCGCCGGGAGGG
65 pGEX5X MeCP2 S204X AGAATTCGCCTCCCCCAAACAG
66 pGEX5X MeCP2 S204X CTCGAGTCACGTGGCCGCCTTG
67 pGEX5X MeCP2 R106W AGAATTCATGGTAGCTGGGATGTTAGGG
68 pGEX5X MeCP2 R106W CTCGAGTCAGCTAACTCTCTCGGTC
69 pGEX5X MeCP2 F155S AGAATTCATGGTAGCTGGGATGTTAGGG
70 pGEX5X MeCP2 F155S CTCGAGTCAGCTAACTCTCTCGGTC
71 pGEX5X MeCP2 R294X AGAATTCATGGTAGCTGGGATGTTAGGG
72 pGEX5X MeCP2 R294X CTCGAGTCATCGGATAGAAGACTCCTTC
73 pGEX5X MeCP2 F155S/R294X AGAATTCATGGTAGCTGGGATGTTAGGG
74 pGEX5X MeCP2 F155S/R294X CTCGAGTCATCGGATAGAAGACTCCTTC
75 pGEX5X MeCP2 H370X AGAATTCATGGTAGCTGGGATGTTAGGG
76 pGEX5X MeCP2 H370X CTCGAGTCAGTGATGGTGGTGGTGC
77 pGEX5X MeCP2 E397X AGAATTCATGGTAGCTGGGATGTTAGGG
78 pGEX5X MeCP2 E397X CTCGAGTCACTCGGAGCTCTCGG
79 pGEX5X MeCP2 R453X AGAATTCATGGTAGCTGGGATGTTAGGG
80 pGEX5X MeCP2 R453X CTCGAGTCATCGGTGTTTGTACTTTTCTG
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